Woodline Partners’s Arbutus Biopharma ABUS Stock Holding History
Bought
Maintained
Sold
Other funds holding ABUS
Woodline Partners's ABUS Position: Q3 2026 in Review
Woodline Partners sold out of Arbutus Biopharma (ABUS) in Q3 2026, closing a stake of 2,281,856 shares — an estimated $11M sold.
Woodline Partners first reported a position in ABUS in Q1 2021 and held it in 16 quarters. The position peaked at $11.8M in Q4 2023. 214 funds tracked by Wall St. Rank hold ABUS as of Q3 2026.
- Woodline Partners reported no remaining Arbutus Biopharma position as of Q3 2026 after selling out during the quarter.
- Woodline Partners sold 2,281,856 Arbutus Biopharma shares in Q3 2026, an estimated $11M.
- Woodline Partners first reported a position in Arbutus Biopharma in Q1 2021 and held it in 16 quarters.
- Woodline Partners's Arbutus Biopharma position peaked at $11.8M in Q4 2023.
- 214 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2026.
Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.